Latigo Biotherapeutics
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 1 year.
- Recent price momentum is -39.3% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has risen to 1.4% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Performance
Key statistics
Price & volume
- Prev close
- 13.24
- Open
- 13.22
- Day range
- 11.91 - 13.35
- Avg price
- 12.99
- Volume
- 267.17K
- Turnover
- 3.47M
- Turnover ratei
- 1.67%
- Volume ratioi
- 0.70
- Amplitudei
- 10.88%
- 52-week rangei
- 10.24 - 25.93
Valuation
- P/Ei
- -7.16
- P/E (TTM)i
- -8.03
- P/Bi
- 2.19
- EPSi
- -1.82
- Book value / shi
- 5.94
- Net profit
- -120.33M
- Net assets
- 393.95M
Share structure
- Market cap
- 861.89M
- Float capi
- 208.00M
- Shares out
- 66.30M
- Float sharesi
- 16.00M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2026-08-07
49.9% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-7.10M net over the window
Short interest
- Shares short
- 941.43K
- % of floati
- 1.42%
- Days to coveri
- 5.43
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Latigo Biotherapeutics (LTGO)?
Latigo Biotherapeutics last traded at 13.00. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Latigo Biotherapeutics's market cap?
About 861.89M.
What is the P/E ratio of Latigo Biotherapeutics?
The trailing twelve-month P/E is -8.03. The Valuation tab shows it against the stock's own five-year range.
Does Latigo Biotherapeutics pay a dividend?
Latigo Biotherapeutics does not currently pay a regular dividend.
Is Latigo Biotherapeutics a buy according to analysts?
The consensus of 3 analysts is a Buy rating, with an average 12-month price target of 57.67, which implies 343.6% upside from the current price. This is not investment advice.
What is Latigo Biotherapeutics's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Latigo Biotherapeutics a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-11-20 16:26:22 · For reference only, not investment advice and not tailored to your situation.
Latigo Biotherapeutics discussion 0 comments